Mustang Bio, Inc. SG&A Expenses

SG&A Expenses of MBIO for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending June 29, 2021 was $2.5 Million (a -27.4% decrease compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 17.39%
  • Annual SG&A Expenses for 2020 was $9.4 Million (a -0.67% decrease from previous year)
  • Annual SG&A Expenses for 2019 was $9.46 Million (a 39.96% increase from previous year)
  • Annual SG&A Expenses for 2018 was $6.76 Million (a -39.69% decrease from previous year)
  • Twelve month SG&A Expenses ending June 29, 2021 was $10.4 Million (a -4.29% decrease compared to previous quarter)
  • Twelve month trailing SG&A Expenses increased by 14.78% year-over-year
Trailing SG&A Expenses for the last four month:
29 Jun '21 30 Mar '21 30 Dec '20 29 Sep '20
$10.4 Million $10.9 Million $9.43 Million $9.1 Million
Visit stockrow.com/MBIO for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of Mustang Bio, Inc.

Most recent SG&A Expensesof MBIO including historical data for past 10 years.

Interactive Chart of SG&A Expenses of Mustang Bio, Inc.

Mustang Bio, Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $2.5 $3.44
2020 $2.38 $2.13 $2.97 $1.96 $9.4
2019 $2.05 $1.99 $3.19 $2.34 $9.46
2018 $1.68 $1.34 $1.68 $2.06 $6.76
2017 $3.12 $4.6 $1.67 $2.03 $11.21
2016 $1.0 $1.1 $0.46 $0.26 $2.82
2015 $0.09

Business Profile of Mustang Bio, Inc.

Sector: Healthcare
Industry: Biotechnology
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.